GMED NYSE Week ended 31 Jul 2026

Weekly Investor Report

Globus Medical · Healthcare · Medical Devices

Open interactive chart View report data
Latest close 78.79 USD
3.0% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -8.1% below the Trend Line and sits at 53.7% of its 52-week range. The latest completed week returned 3.0%, after a -1.7% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 60/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 32 out of 100
Latest Close 78.79 USD 31 Jul 2026
1W Return 3.0% latest completed week
4W Return -1.7% short-term follow-through
12W Return 1.1% quarterly tape
Trend Breadth 50.0% 26 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 3.0% Latest completed week; four-week move -1.7%. Indicator stack 28/23 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 60/100 conviction; expected move 13.0%. News sentiment 57/100 69 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -8.1% below the Trend Line and sits at 53.7% of its 52-week range. The latest completed week returned 3.0%, after a -1.7% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2012-week average 0.34

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership2/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.20Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers11 reversal markers

No recent accumulation markers. 1 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -1.7% over four weeks, 1.1% over 12 weeks, and 49.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W3.0%
4W-1.7%
12W1.1%
26W-13.1%
52W49.7%
Active trend streak0 weeks
Active weeks in one year26
Trend breadth50.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.14Latest activity-pressure read.
Pressure change-85.0%Four-week change in activity pressure.
Leadership-8.73Latest relative-leadership reading.
RS change-46.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 97% Model confidence 93%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength77/100Blend of value, momentum, and quality. Underlying universe rank 24; rank 1 is best.
Value36/100Relative valuation strength. Underlying universe rank 65; rank 1 is best.
Quality94/100Profitability and accounting quality. Underlying universe rank 7; rank 1 is best.
Momentum85/100Medium-term price momentum. Underlying universe rank 16; rank 1 is best.
Growth99/100Revenue and earnings growth. Underlying universe rank 2; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework63/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
17.7x
Price divided by trailing earnings.
Price / sales
3.3x
Market value relative to trailing revenue.
EV / EBITDA
11.3x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
9.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
67.9%
Gross profit retained from each unit of revenue.
Operating margin
19.3%
Operating profit retained from revenue.
Free-cash-flow margin
30.9%
Free cash flow generated from revenue.
Return on invested capital
12.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
23.5%
Latest one-year revenue growth.
EPS growth
216.2%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
23.7%
Latest one-year free-cash-flow growth.
Piotroski F-score
8/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.1%
Net share repurchases relative to market value.
Shareholder yield
0.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

GMED shows volatility options pressure with a 60/100 conviction score, put-call volume ratio of 0.00, expected move of 13.0%, and Sharemaestro trend signal inactive.

Conviction60/100
Expected move13.0%
Put/call volume0.00
Pressure100
Speculation42
Volatility88
Trend agreement0
Open options detail
Insider activity2 / 3

2 acquisitions and 3 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment57/100

Weighted news tone is neutral across 69 relevant articles.

24 positive · 42 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move13.0%Nearest-chain priced movement where available.
52-week drawdown-22.3%Distance below the 52-week high.
13-week volatility6.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+10.7%Week of 22 May.
Worst week-14.7%Week of 8 May.
Latest week+3.0%Week of 31 Jul.

Shape of recent returns

Strong gains5
Modest gains6
Flat weeks0
Modest losses12
Sharp losses3
Recent vol6.1%13-week weekly-return volatility.
Base vol7.2%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew5.6% / -3.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape30/100

Trend, activity pressure, participation, and risk combine to a 30/100 tape read.

 Indicator analysis13/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 2/12.

Activity pressure 0.20; 1 reversal markers Factors73/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 42; Small Cap Core rank 72 SVQF63/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 380.0 of 1013 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options38/100

GMED shows volatility options pressure with a 60/100 conviction score, put-call volume ratio of 0.00, expected move of 13.0%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 13.0% Sentiment57/100

Weighted news tone is neutral across 69 relevant articles.

Globus Medical (GMED) Stock Could Be Undervalued Following Q2 Earnings Date Insiders2 / 3

2 acquisitions and 3 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202678.79 USD3.0%85.75 USD69.25 USD-1.14-8.735.8MOff
24 Jul 202676.49 USD-0.7%86.03 USD69.11 USD-0.99-10.126.6MOff
17 Jul 202677.00 USD-1.4%86.43 USD69.01 USD-0.66-9.8011.4MOff
10 Jul 202678.11 USD-2.5%86.77 USD68.91 USD-0.65-9.728.6MOff
3 Jul 202680.12 USD-7.1%87.05 USD68.81 USD-0.62-5.968.8MOff
26 Jun 202686.25 USD8.9%87.42 USD68.66 USD-0.703.6410.3MOff
19 Jun 202679.23 USD-1.4%87.58 USD68.49 USD-0.88-6.728.1MOff
12 Jun 202680.39 USD0.5%87.80 USD68.36 USD-0.77-4.357.7MOff
5 Jun 202680.00 USD-2.3%87.94 USD68.22 USD-0.80-4.138.2MOff
29 May 202681.88 USD-3.5%88.07 USD68.06 USD-0.78-4.217.7MOff
22 May 202684.81 USD10.7%87.35 USD67.90 USD-0.690.7710.6MOff
15 May 202676.64 USD-1.7%86.60 USD67.69 USD-0.64-7.979.9MOff
8 May 202677.95 USD-14.7%86.03 USD67.56 USD-0.42-6.2112.5MOn
1 May 202691.34 USD-3.7%85.32 USD67.43 USD-0.3012.604.4MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.